Form D · Biotechnology

Optofluidics, Inc.

Burlingame, CA · CIK 0001762996

Offering snapshot reported Dec 29, 2022 · SEC filing

Reported sold: $7M
Investors reported: 11
Minimum accepted: $0
First sale: Jun 30, 2022

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$5,999,994 → $6,999,990

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Dec 29, 2022	Amendment	$6,999,990	$999,996vs Jul 11, 2022	11	SEC filing
Jul 11, 2022	Initial	$5,999,994	No comparison	11	SEC filing
Apr 13, 2020	Initial	$6,738,727	No comparison	14	SEC filing
Dec 27, 2018	Initial	$5,645,007	No comparison	6	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-451732

Source: Form D, filed Dec 29, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Bernardo Cordovez	Executive
Rick Gordon	Director, Executive
Robert Hart	Executive
Shahram Hejazi	Director
Joseph Keegan	Director
Casey Mc Glynn	Executive
William Snider	Director
Chad Souvignier	Director
Robert Wicke	Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

1828 El Camino Real Suite 703
Burlingame, CA, 94010